8/13/09 A panel of advisors to the Food and Drug Administration (FDA) is slated to review a new kind of osteoporosis drug on August 13. The agency is not bound by the recommendations of its advisory panels, but typically follows them.
The drug, denosumab, which may be brand-named Prolia, is a monoclonal antibody given by injection every six months, and it works by inhibiting a protein necessary to cells called osteoclasts, which break down bone.
In a head-to-head comparison with alendronate (Fosamax) published in the February 23, 2006 issue of The New England Journal of Medicine, denosumab increased bone density at the hip and spine at least as well, and in some cases, better than alendronate.
Sorry you had such a hard time on Reclast.
Denosumab, however, is not the same kind of drug.
If the FDA signs off in the next few weeks, Denosumab will be the first biologic drug approved to treat osteoporosis.
You can read a more in-depth report on it here:
http://www.arthritistoday.org/news/denosumab-review.php
Kind regards,
Brenda Goodman
AUGUST 18,A LONG TIME TO FEEL BETTER .
Leave a Comment